Microbiologics Introduces SARS-CoV-2 Products for Quality Control and Research
The company’s latest covid-19 products include a protein-coated RNA process control, and an in vitro diagnostics control with pooled gene targets.
Read MorePosted by Laurie Bonner | May 8, 2020 | Covid 19 |
The company’s latest covid-19 products include a protein-coated RNA process control, and an in vitro diagnostics control with pooled gene targets.
Read MorePosted by Laurie Bonner | May 8, 2020 | Covid 19 |
The new solution is designed to enable laboratories to enter biospecimens into a biobank and rapidly begin conducting covid-19-related testing and research.
Read MorePosted by Laurie Bonner | May 7, 2020 | Covid 19 |
Microproof SARS-CoV-2 screening/identification kits run on many commonly used real-time PCR instruments. The test returns results in less than 1.5 hours.
Read MorePosted by Laurie Bonner | May 7, 2020 | Covid 19 |
Genalyte currently has the capacity to test 250,000 patients per month; the company is scaling up to test more than 7,500,000 patients per month by September.
Read MorePosted by Laurie Bonner | May 7, 2020 | Covid 19 |
In the United States, the digital pathology software will support the need for remote pathology brought about by the covid-19 pandemic.
Read More